×

RNS Number : 9540T

Integumen PLC

20 November 2019

 

AIM share code: SKIN

 

20 November 2019

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen announces successful results of AI water research project

 

Rinocloud AI remotely detects contaminated water with 99.3% accuracy in 3.37 seconds

 

 

Integumen today announces the successful results of a three-year development Remote Automated Water Test research project (RAWTest), using Artificial Intelligence (AI) in a consortium partly funded by the Irish Environmental Protection Agency (EPA).  

 

The Project

The consortium comprised of the Irish Environmental Protection Agency (EPA), Cork Institute of Technology's (CIT) Centre for Advanced Photonics & Process Analysis (Cappa Group), the CIT Nimbus embedded systems research institute and the AI team from Integumen's Rinocloud subsidiary. 

 

Rinocloud's AI platform was used to test water samples from a fully autonomous data buoy deployed on the Inniscarra Water Reservoir in Cork, Ireland, for E.coli, a bacterium that can cause illness in humans, including diarrhoea, abdominal pain, fever and sometimes vomiting.

 

Results: The positive detection of E.coli bacteria in the water was detected with 99.3% accuracy in 3.37 seconds.  This compares to current standard test detection time of between 5-7 days.

 

Gerard Brandon, CEO of Integumen plc, comments:

"Integumen continues to lead the way with practical demonstrations of solutions for real-world problems.  Remote detection of water contamination across the globe is a first and third world problem with future climate change threatening to increase flooding and contribute to water shortages.  This means increased reliance on recycling and recovery of water supplies, which in turn requires wireless monitoring of all water supplies before consumer consumption.  RAWTest, we believe, can contribute to keeping our water, and healthcare, safe."

 

Wireless RAWTest

·      Rinocloud's AI engine analysed wireless transmission of water data for 13 key AI features, which work as indicators, from 1000+ data elements identified by Raman Spectroscopy.

·      Results showed a 99.3% accuracy in identifying E.coli in water

·      A system of exception alarms was set up by email to escalate a positive sample to the appropriate control group

·      All data was immediately available on the secure Rinocloud portal for access by approved parties for immediate action

·      Potential for other microscopic parasite detection, e.g. Cryptosporidium and Giardia, following data samples input.

 

Water Scarcity:

Water scarcity is the lack of freshwater resources to meet water demand.  It affects every continent and was listed in 2019 by the World Economic Forum as one of the largest global risks in terms of potential impact over the next decade[i].

 

The deployment of wireless RAWTest Buoys in water treatment plants would be a world first and have a positive impact on water consumer service metrics, reducing the average length of time water would be shut off in the event of contamination, reduced "boil-water" notices and faster time to restore supply, as well as biological quality.
 

RAWTest Opportunities:

·      With 20 species of Listeria bacterium, every public building including hospitals, hotels, conference halls and senior citizen nursing homes are at risk of contamination

·      Remote detection and analysis of malaria in blood in third world-countries and for military use

·      In-line milking machines could detect mastitis in a single cow, enabling instant action to eliminate contamination with a dairy herd milk collection

·      Early warning system in fermentation processes for ethanol, alcohol and wine producers at risk of bacterial hazard to improve consumer safety, shelf-life stability and longevity

 

Contacts

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About Integumen: www.integumen.com

Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with four business units: 

 

·      Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services.  Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

·      Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.

·      Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.

·      Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.

 

About RNS Reach announcements

RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

 

---

[i] https://www.weforum.org/reports/the-global-risks-report-2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAEASFNFDPNFFF

Close

×

RNS Number : 1821T

Integumen PLC

13 November 2019

 

AIM share code: SKIN

 

13 November 2019

 

Integumen PLC

 

("Integumen" or "Company")

 

Integumen shares revenue to deliver AI data solutions across Parity plc UK NHS clients

 

Trading update provides 2020 guidance of £4m prior to Parity Agreement

 

 

Integumen announces that it has signed Heads of Terms with Parity plc to enter a multi-year Framework Agreement ("Agreement") to be completed on or before the 18 December 2019 for the supply of Artificial Intelligent ("AI") software across Parity's National Health Service ("NHS"), Central Government and Private Institutional clients.

 

This Agreement creates an opportunity to cross-sell intelligent data management, extracting value using analytics, with a focus on proving return on investment, to Parity's 150+ institutional clients.  The software includes full GDPR compliance with secure cloud data migration from existing legacy systems to a digital workplace through the military grade encryption "Drive4Growth" AI platform powered by Integumen's Rinodrive.

 

Combined benefits:

·      Recurring shared revenue streams for both Parity and Integumen in 2020

·      Value-added proposition in demand from Parity clients with c. 3 to 5-year annual contracts

·      Immediate access to 150 public and private institutional clients

·      Trusted approved vendor for Government and private sectors for over 45 years

·      1,000+ data experts and 100+ enterprise sales and office professionals

·      Existing cross-over access to educational institutional research facilities

·      Access to multiple industry, public and private sector distribution routes to market

·      Well defined roadmap to next level business growth for both Parity and Integumen

 

Six-month trading update:

In May 2019, Integumen acquired Rinocloud Limited for £3m to enable LabskinAI to uses the Rinodrive AI platform to provide cloud-based data services to Integumen's Top 20 global skincare clients.  By the end of June 2019, Rinocloud reached monthly profitability, and over the last six months (May to October) exceeds revenue from Labskin this financial year.

 

Outlook:

Since 2018, the Company has seen average sales grow from £5k for consumable, one-off sales to 2019 average sales of £50k as a service contract.  Heading into 2020, Integumen is engaging with multiple top 20 global skin and personal care companies and believes average sales are likely to range between £100k to £500k for data as a service to skincare R&D framework multi-year agreements, providing good visibility of revenue.  Therefore, excluding developments that may arise from Integumen entering into the agreement with Parity Group plc, the Company is guiding 2020 revenues of £4m.

 

Gerard Brandon, CEO of Integumen plc, comments:

"We are delighted to be able to roll-out the Drive4Growth AI platform in partnership with the credibility and reputation that Parity data experts hold, with an extensive, if not exhaustive, list of public and private institutions. We look forward to working alongside Parity to extract greater value for their clients and contribute to the transformation of the UK's National Health Service, public and private institution data over the next few years."

 

Matthew Bayfield, CEO of Parity Group plc, comments:

"Parity is pleased to be partnering with Integumen and rolling out the Drive4Growth AI platform to our client base.  We have been working with many of the same clients for 45 years, so we understand their needs.  With healthcare sector data growth in 2020 expected to double every 73 days, our clients need to securely manage and extract greater value using analytics and AI in order to make important decisions.  The Drive4Growth AI platform delivers on those requirements, increases revenue per client, increases client contract term and generates a higher margin, leading to greater profitability."

 

Contacts

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About Integumen: www.integumen.com

Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with four business units: 

 

·      Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services.  Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

·      Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.

·      Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.

·      Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.

 

About Parity Group: www.parity.net

Parity helps organisations find the right people, skills and data to support data-led business decisions. Providing advice on data and with access to qualified personnel with skills offered, either as a managed service, through resourcing in the contract or permanent market or as part of a learning and development programme.

Income derives from a mix of long-term contracts with public and private sector organisations as well as expanded projects with existing clients as a result of strong relationships and a track record of high client satisfaction. Key highlights comprising of:

·      Over 45 years of expertise in public and private recruitment and service contract sector

·      More than 100 employees across the UK

·      Client numbers exceed 150 in both UK and Ireland

·      Associate numbers supporting client services exceeds 1,000

 

RinoDrive "Drive4Growth": www.rinodrive.com

A fully integrated set of software tools that can ingest data, in any volume, from any source in any format, interact with it, learn from it and enrich it to unlock insights and discoveries.

This data management solution was developed by scientists and engineers with experience in software, sensors, AI, optofluidic research, fintech, green-tech, travel and healthcare.

It was designed to allow interaction, in a cyber-secure environment, with commercially sensitive data, and to share insights across multi-disciplinary teams, generating different data formats, from multiple sources, located in different countries.

RinoDrive delivers big data, AI functionality and world class infrastructure to large companies with big data problems. These include financial services, education and life science companies. Most recently completing the automation of laboratories and application of AI to unearth more knowledge about the skin microbiome. This led to the acquisition in May 2019 by Integumen PLC, to secure access to, and the exploitation of data from some of the largest cosmetic, pharmaceutical and medical companies in the world.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCFFIFWEFUSELF

Close

×

RNS Number : 4744S

EVR Holdings PLC

06 November 2019

 

                                                                                                              Wednesday, 6th November 2019

 

 

MELODYVR EXTENDS PARTNERSHIP WITH GOOD MORNING AMERICA

 

EVR Holdings plc (AIM:EVRH), the leading creator of virtual reality entertainment content and operator of the MelodyVR platform, is pleased to announce that next Wednesday November 13th the Company will extend its partnership with Good Morning America ("GMA") and ABC to broadcast a landmark event live from the heart of Nashville.

 

A global audience will be able to experience America's most-watched morning show in full immersive 360-degree virtual reality on their smartphones via the MelodyVR app, downloadable from the iOS, Google Play and Oculus app stores (or via this link on.melodyvr.com/App).

 

Transmitted from Music City's iconic Wildhorse Saloon, MelodyVR users will get a unique look at Country Music Association Award nominees Luke Combs and Maddie and Tae, as well as country music legends Trisha Yearwood and Trace Adkins during their appearance on Good Morning America.

 

Thanks to MelodyVR's groundbreaking live-stream VR technology, an unlimited global audience will be able to experience the program up close in full immersive virtual reality.

 

By selecting different Jump Spots — a function that is unique to the MelodyVR platform — viewers can choose their location within the saloon, getting them incredibly close to their music heroes. MelodyVR will also give users a rare glimpse of their favourite country stars behind the scenes.

 

MelodyVR has already proven itself to be a firm favourite of country music fans over the last year, with exclusive virtual reality performances from the likes of CMA nominees Blake Shelton, Thomas Rhett, and Midland, as well as Kelly Clarkson and Hunter Hayes available on the platform.

 

"I don't know if you want me in your living room, but if you do, we made that happen," says double Award nominee Luke Combs. "It's so cool that people around the world can get up close to the show in Nashville with MelodyVR and Good Morning America. CMA Awards day will be so exciting for me after one hell of a year and being able to share that moment with my fans in VR is real special."

 

Anthony Matchett, CEO of MelodyVR says: "We are delighted to be working with the ABC and Good Morning America team again, after recently partnering with them to broadcast Marshmello and Kane Brown in virtual reality during the renowned Summer Concert Series to fans across 15 countries. It's great to be right at the heart of the action during the biggest day in the country music calendar, and it's a privilege to allow fans around the world to feel as though they're right here in Nashville, as award excitement builds."

 

For further information please contact:   EVR Holdings plc Anthony Matchett, Executive Chairman & CEO                                                                            [email protected]

Arden Partners plc: Nominated Advisor and Sole Broker                                                        Tel: +44 (0) 20 7614 5900 Corporate Finance: Ciaran Walsh / Ruari McGirr / Ben Cryer Corporate Broking: Simon Johnson

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAFSUFSMFUSEFF

Close

×

RNS Number : 0577S

ZAIM Credit Systems PLC

04 November 2019

 

Not for release or distribution, directly or indirectly, within, into or in the United States or to or for the account or benefit of persons in the United States, Australia, Canada, Japan or any other jurisdiction where such offer or sale would violate the relevant securities laws of such jurisdiction

 

For Immediate Release

4 November 2019

Zaim Credit Systems Plc

("Zaim Credit" or "the Company")

Admission to Trading

The Directors of Zaim Credit, a regulated microfinance business operating in the Russian Federation, are pleased to announce that following the publication of its prospectus on 30 October 2019 (the "Prospectus") and completion of the placing and subscription of 104,000,000 new ordinary shares of £0.01 each in the Company ("Ordinary Shares") at 2.5p per share ("Placing Price") raising gross proceeds of £2.6 million, the Company's Enlarged Share Capital comprising 436,975,000 Ordinary Shares will be admitted to the Official List (by way of a Standard Listing under Chapter 14 of the Listing Rules) and to trading on the London Stock Exchange's Main Market for listed securities at 8.00 a.m. GMT today under the TIDM "ZAIM" ("Admission"). The Company's ISIN is GB00BK5T9G03 and LEI 213800Z4MI9KSZA2VW72.

Siro Cicconi, Chief Executive Officer commented:

"We are pleased to bring the Company to the London Market. We believe there are excellent prospects to grow our business and look forward reporting further progress in due course."

About the Company

 

Zaim Credit is the holding company of a Russian based financial services company Zaim-Express LLC ("Zaim") which it acquired on 10 September 2019. Zaim is authorised to conduct microfinance activities and included on the State Registry of Microfinance Organisations (the "Registry") maintained initially as a microcredit organisation ("MCO") by the Russian Ministry of Finance and later, by the Central Bank of Russia ("CBR").

 

Zaim's MCC status allows it to engage in microfinance activity in the territory of the Russian Federation and since obtaining its authorised status, Zaim has developed a bespoke IT system, created a distribution network and raised debt capital to fund its loan book.

 

Copies of the Prospectus are available on the Company's website at http://www.zaimcreditsystemsplc.com/en/ and during normal business hours at the registered address of the Company at c/o Hill Dickinson LLP, The Broadgate Tower, 20 Primrose Street, London, EC2A 2EW.

Total Voting Rights

In conformity with Rule 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules, the Company confirms that as from Admission the total number of voting rights in the Company is 436,975,000. This figure may be used by the Company's shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

Director / PDMR Shareholding

As set out more fully in the Prospectus, certain Directors and members of the Company's senior management have been allotted Fee Shares and granted Options on Admission. As the Directors and senior managers are persons discharging managerial responsibilities, copies of the notifications relating to such transactions in the Company's securities are set out in Appendix I at the end of this announcement.

Defined terms in this announcement shall have the same meanings as in the Prospectus.

Enquiries:

Zaim Credit Systems Plc
Simon Retter Siro Cicconi	Tel: +44 (0) 7795 640 616 Tel: +39 33 3886 6733
Beaumont Cornish Limited
Roland Cornish / James Biddle	Tel: +44 (0) 20 7628 3396
Optiva Securities Limited
Jeremy King / Vishal Balasingham	Tel: +44 (0) 20 3137 1902

 

Appendix I

This announcement is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation ("MAR") and the Company confirms that the PDMR's notification obligations under MAR have been satisfied.

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Simon Retter Stonedale Management and Investments Ltd
2	Reason for notification
a)	Position / status	Finance Director
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Ordinary Shares and Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Ordinary Shares and Issue of Options
	Price(s) and volumes(s)	Financial Instrument Price(s) Volumes(s) Ordinary Shares 2.5p 1,600,000 Options* 2.5p 6,450,000 *Options have been issued to Stonedale Management and Investments Ltd of which Simon Retter is the sole director and sole shareholder
d)	Aggregated information	Financial Instrument Price(s) Volumes(s) Total Value Ordinary Shares 2.5p 1,600,000 £40,000 Options* 2.5p 6,450,000 £161,250 *Options have been issued to Stonedale Management and Investments Ltd of which Simon Retter is the sole director and sole shareholder
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Siro Cicconi
2	Reason for notification
a)	Position / status	CEO
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Options
	Price(s) and volumes(s)	Price(s) Volumes(s) 2.5p 10,750,000
d)	Aggregated information	Price(s) Volumes(s) Total Value 2.5p 10,750,000 £268,750
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Vladimir Golovko
2	Reason for notification
a)	Position / status	COO
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Options
	Price(s) and volumes(s)	Price(s) Volumes(s) 2.5p 8,600,000
d)	Aggregated information	Price(s) Volumes(s) Total Value 2.5p 8,600,000 £215,000
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Malcolm Groat
2	Reason for notification
a)	Position / status	Non-Executive Chairman
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Options
	Price(s) and volumes(s)	Price(s) Volumes(s) 2.5p 2,150,000
d)	Aggregated information	Price(s) Volumes(s) Total Value 2.5p 2,150,000 £53,750
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

1	Details  of  the  person  discharging  managerial  responsibilities  /  person  closely associated
a)	Name	Andrey Katyshkov
2	Reason for notification
a)	Position / status	CFO
sb)	Initial notification /Amendment	Initial
3	Details of the issuer,  emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Zaim Credit Systems Plc
b)	LEI	213800Z4MI9KSZA2VW72
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description  of  the financial instrument, type of instrument Identification code	Options     ISIN: GB00BK5T9G03
	Nature of the transaction	Issue of Options
	Price(s) and volumes(s)	Price(s) Volumes(s) 2.5p 4,300,000
d)	Aggregated information	Price(s) Volumes(s) Total Value 2.5p 4,300,000 £107,500
e)	Date of the transaction	2019-11-04
f)	Place of the transaction	Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCEANFFELANFFF

Close

×

Neville Registrars is delighted to welcome Zaim Credit Systems Plc as the newest addition to its list of client companies.

Zaim Credit Systems Plc is the holding company of a Russian based financial services company Zaim Express LLC

Further information can be found on the Company's website: http://www.zaimcreditsystemsplc.com

 

 

 

Close

×

RNS Number : 8050R

Pennant International Group PLC

31 October 2019

 

                                                                                                                                                           

FOR IMMEDIATE RELEASE                                                                    31 October 2019

 

PENNANT INTERNATIONAL GROUP PLC

 

New £3.4 Million Contract Award and Qatar Update

 

Pennant International Group plc ("Pennant", the "Group", or the "Company"), the AIM quoted supplier of integrated training and support solutions, products and services which train and assist operators and maintainers in the defence and regulated civilian sectors, is pleased to announce the following contracts update.

 

New Contract Award

 

Pennant has been awarded a major new contract by a UK OEM valued at circa £3.4 million for the design and build of a helicopter maintenance training aid which will comprise a full-size representation of the relevant airframe to enable UK military training on 'anti-surface' weapons systems.

 

The contract is an engineered-to-order programme, whereby revenue will be recognised on a 'percentage of cost completed' basis, as the programme runs across 2020 and 2021, with final acceptance due in Q4 2021.

 

Qatar Progress

 

As previously announced, the Group had budgeted to realise key revenue streams in the second half of 2019 upon acceptance of training aids for the Qatar programme.

 

Pennant is now pleased to report that all four IAMT devices for Qatar have achieved acceptance, enabling the revenues and profits associated with those training aids to be recognised in the current year.

 

Two further products are on schedule for acceptance testing in December 2019.

 

Phil Walker, Group CEO, commented: "After a challenging period, it is great to see the hard work of Pennant's staff pay off, with products being successfully completed on schedule and on budget for the Qatar programme, plus the conversion of one of a number of key opportunities in our substantial single-source pipeline into a valuable contract award."

 

 

Certain information contained in this announcement would have constituted inside information (as defined by Article 7 of Regulation (EU) No 596/2014) ("MAR") prior to its release as part of this announcement and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

Enquiries:

 

Pennant International Group plc	www.pennantplc.co.uk
Philip Walker, CEO David Clements, Commercial & Risk Director	+44 (0) 1452 714 914
WH Ireland Limited (Nomad and Broker)	www.whirelandcb.com
Mike Coe Chris Savidge	+44 (0) 117 945 3470
Walbrook PR (Financial PR)	[email protected]
Paul Vann Tom Cooper	+44 (0)20 7933 8780 Mob: +44 (0)7768 807631

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTEAEEFDLLNFFF

Close

×

RNS Number : 5911R

Sativa Group PLC

30 October 2019

 

Press Release

30 October 2019

Sativa Group Plc

 

("Sativa" or "the Company" or "the Group") 

 

Access gained to retail-majors through distribution agreement with

SHS Sales & Marketing (GB) Limited 

 

Brand name change of George Botanicals to Goodbody Botanicals 

 

Sativa Group Plc [NEX: SATI], the UK's leading quoted CBD wellness and medicinal cannabis Group, is pleased to announce that its wholly owned subsidiary, George Botanicals, has entered into a brand partnership agreement with SHS Sales & Marketing (GB) Limited ("SHS Sales & Marketing").  SHS will distribute a range of "Goodbody Botanical" branded products to UK high street grocery, pharmacy and specialist customers retailers.  

 

SHS Sales & Marketing distributes over 100 blue chip Fast-Moving Consumer Good brands in the UK and Republic of Ireland including Mars, Colgate, Lemsip and Nurofen.  SHS Sales & Marketing enjoys a market penetration to over 90% of UK households by distributing high quality products to the major high street retailers and leading convenience chains such as Sainsbury's, ASDA, Tesco, and Waitrose, as well as to pharmacies and health and wellness stores such as Holland & Barrett. 

 

As part of the distribution agreement, SHS Sales & Marketing will market the Goodbody Botanicals range on an exclusive basis to its customer base, advising on product mix along with providing promotional and communications support.  Logistics and invoicing are also included within the contract. 

 

In tandem with this significant brand partnering agreement, George Botanicals is re-branding its highly successful George Botanicals product range to "Goodbody Botanicals".  In this process the Goodbody Botanicals branding and packaging has been significantly upgraded, providing additional product information for customers.  All products are tested and certified by Phytovista laboratories and are THC free.  

 

Henry Lees-Buckley, Chief Executive of Sativa, said: "We are thrilled to be partnering with the highly regarded and successful team at SHS.  The combination of their sales, marketing and logistics support, coupled with our high quality Goodbody products, make a compelling value proposition for major high street retailers".

 

John Heynen, Managing Director of SHS Sales & Marketing GB said: " The growing demand for CBD wellness products in the UK provides us with an opportunity to further extend our offer to our customers and shoppers, and it is critical we work with the best partner to realise this.  All Goodbody Botanical products are rigorously tested to ensure that they bring high quality items to the marketplace. This attention to product development, quality and testing will provide our customers the sales opportunity and security they need".

 

For further information please contact: 

 

Henry Lees-Buckley  Chief Executive Officer Sativa Group Plc  +44 (0) 20 7971 1255   [email protected]   www.sativagroup.co.uk	Joseph Colliver Chief Financial Officer Sativa Group Plc  +44 (0) 20 7971 1255   [email protected]    www.sativagroup.co.uk
NEX Exchange Corporate Adviser   Corporate Finance    Stephen Keys / Max Gould  Cenkos Securities plc  +44 (0) 20 7397 8900
Equity Sales    Julian Morse Cenkos Securities +44 (0) 20 7397 8900
Financial PR and IR   Abchurch Communications Julian Bosdet +44 (0)207 4594 4070   +44 (0) 7771 663 886	[email protected] www.abchurch-group.com

 

Notes to Editors. 

Sativa Group Plc is the UK's leading quoted CBD wellness and medicinal cannabis group with five operating subsidiaries. 

Goodbody Botanicals provides CBD products online and to retail markets including pharmacies, wellness stores and grocers.  Goodbody Wellness is a high-street retail brand with dedicated CBD wellness stores providing a premium shopping experience to consumers.  Tessellate Collective is a direct-selling network marketing platform servicing consumers at home.  Phytovista laboratories provides independent testing of CBD products to both external customers and fellow Group businesses. 

 

Sativa Grow holds a Controlled Drug licence and cultivates cannabis plants to fulfil its partnership agreement with King's College London to research the impact of cannabinoids on inflammation and respiratory conditions.  

 

 – Ends –

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRAQBLBXKBFXFBB

Close

×

RNS Number : 3928R

Integumen PLC

29 October 2019

 

AIM share code: SKIN

29 October 2019

 

Integumen PLC

 

("Integumen" or "Company")

 

 

Integumen launches independent Rinodrive AI open-source eco-system

 

Labskin AI demonstrates value of the Rinodrive data driven platform

 

Integumen is pleased to announce the launch of Rinodrive (www.rinodrive.com) as an independent Artificial Intelligent (AI) platform for collaboration and joint venture partners as an open-source cloud-based eco-system. The stand-alone platform is currently being rolled out with existing healthcare clients, a growing list of higher educational establishments, being tested in government departments, in a reputable UK bank and an international financial advisory firm.

 

Since 2016, Rinocloud, a wholly-owned subsidiary of Integumen, has developed Rinodrive as a data aggregation, refining and AI analysis open-source eco-system, designed to provide third-party service providers with the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.

 

Gerard Brandon CEO of Integumen commented:

 

"Following the transformational change with the Integumen business model achieved in just a few months by adding AI to Labskin, we are now delighted to be able to offer the same benefits across multiple industries.  Rinodrive will act as an independent AI platform which will allow the management of Integumen to remain focused on their core Labskin AI business while deriving revenues from clients across healthcare services, third-level education, government departments and the financial sector.

 

"In the three years prior to the Rinocloud acquisition in May 2019, Rinodrive had been developed to deal with the explosive growth of data across multiple industries.  We have seen it successfully work with genetic data at Labskin and also at various scientific data at research institutes such as the University College Cork, Cambridge University and the Centre for Advanced Photonics & Process Analysis at the Cork Institute of Technology.  Rinodrive AI is now ready to help our clients and partners advance their work beyond Labskin and add a further revenue sharing source of income as we head into 2020."

 

Explosive data growth

 

It is estimated that the doubling time of medical knowledge in 1950 was 50 years and in 2010, the amount of healthcare data collected was said to be doubling every three and a half years. It is projected that by 2020 this will be every 73 days[i]. The International Data Corporation predicts a healthcare data compound annual growth rate of 36 % up to 2025 – driven by analytics, imaging and real-time data for decision support – exceeding manufacturing (30 %), finance (26 %) and media (25 %)[ii].

 

In order to ensure staff retention while at the same time improve quality of care, it is imperative that healthcare providers increase efficiency to reduce costs, waste, duplication and the length of the care to maintain patient satisfaction. Data is the key driver.

 

Connecting existing systems with open platforms, and specialists with patients, while employing AI to analyse the data and generate actionable insights is key to the increase demands on any modern-day healthcare eco-system.

 

Unexploited data

 

Rinodrive is a robust platform with state-of-the-art open-source cloud infrastructure.  Many Labskin clients already share their clinical trial results through the LabskinAI portal through secure, military grade encrypted access.

 

The business opportunity for Rinodrive will be achieved through partnership, joint venture and revenue sharing collaboration.  Consultant companies managing data aggregation and migration to the cloud can create value for the client from the use of Rinodrive AI tools on their client data. Likewise, recruitment companies supplying IT personnel in a highly competitive market for low-margin single fee income can transform their business model by targeting high margin clients contracting personnel to compete on equal terms with the likes of Accenture, McKinsey and other consultancy firms.

 

 

Integumen plc	Gerard Brandon, CEO	+44 (0) 7340 055 648
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Vassil Kirtchev	+44 (0) 113 370 8974
Turner Pope Investments (TPI) Limited (Broker)	Andy Thacker/Zoe Alexander	+44 (0) 20 3657 0050

 

About Integumen:

Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with three business units: 

 

·     Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services.  Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

·     Rinodrive is a data aggregation, refining and AI analysis open-source eco-system designed to provide third-party service providers the ability to offer their clients valuable insights that support clinical, operational and financial decisions in healthcare services, third-level education, government departments and the financial sector.

·     Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.

·     Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories. 

 

 

---

[i] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116346/

[ii] https://healthitanalytics.com/news/big-data-to-see-explosive-growth-challenging-healthcare-organizations

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCFEWFUAFUSEIS

Close

×

RNS Number : 5567Q

Cadence Minerals PLC

21 October 2019

 

Cadence Minerals Plc

 

("Cadence Minerals", "Cadence" or "the Company")

 

Hastings Technology Metals (ASX:HAS) – DRA Pacific Awarded EPCM Contract Yangibana Processing Plant.

 

Cadence Minerals (AIM/NEX: KDNC; OTC: KDNCY) is pleased to announce Hastings Technology Metals (ASX:HAS) ("Hastings"), Cadence's joint venture partner at the Yangibana Rare Earth Project in the Gascoyne region of Western Australia ("Yangibana Project"), has announced that it has awarded the Engineering, Procurement, Construction and Management (EPCM) contract for its rare earths processing plant and the associated infrastructure for the Yangibana process plant in the Gascoyne Region of Western Australia to DRA Pacific Pty Ltd ("DRA Pacific"), a diversified global engineering, project delivery and operations management. The appointment of DRA Pacific as the EPCM contractor for the Yangibana Project was preceded by a series of value engineering studies and the Front-End-Engineering-Design ("FEED") completed by DRA Pacific during 2018 and 2019.  DRA Pacific's EPCM contract will cover all aspects of the design and construction of the processing facility and associated non-process infrastructure capable of producing 15,000 tonnes of Mixed Rare Earths Carbonate (MREC) per year.

Cadence Minerals Yangibana Holding:

Cadence owns 30% of the Yangibana North, Gossan, Hook, Kanes Gossan, Lions Ear and Bald Hill North Rare Earth Deposit, which form part of the Yangibana Rare Earth Deposit. Probable Ore Reserves of some 2.1 million tonnes at 1.66% total rare earth elements are contained within 30% owned joint venture tenements. Further details of these reserves and pre-feasibility study can be found at: http://irservices.netbuilder.com/ir/cadence/newsArticle.php?ST=REM&id=2688632.

Highlights:

·      DRA Pacific Pty Ltd awarded the Engineering, Procurement and Contract Management (EPCM) Contract for the Yangibana Rare Earths Processing Plant.

·      The scope of works under the DRA Pacific Pty Ltd EPCM agreement has an estimated capital value of circa A$350m.

·      DRA Pacific's parent DRA Global Ltd have extensive experience in designing and building mineral processing facilities worldwide and their personnel have previously delivered rare earth plants in Western Australia.

·      The key component of the contract terms is the comprehensive performance guarantee linked to ore throughput for the entire process flow sheet.

The EPCM contract is the single largest dollar value contract associated with the Yangibana Project.  It is also a fundamental requirement of Hastings' debt providers and hence is pivotal to the project financing process. Works directed under the EPCM Contract have an estimated value of approximately A$350M.

The key component of the contract terms is the comprehensive performance guarantee linked to ore throughput for the entire process flow sheet.

The appointment of DRA Pacific as the EPCM contractor for Hastings represents another critical milestone for the Project, reinforcing that Yangibana is execution ready.

Choosing DRA Pacific was the logical choice given the already close working relationship built up over the last 15 months, and the experience in rare earths processing plant design that DRA Pacific bring to the table.

The full release can be found at: https://www.asx.com.au/asxpdf/20191021/pdf/449nzf57qlq659.pdf

Hastings Executive Chairman Charles Lew said: "We are pleased to have DRA involved in the construction of the Yangibana processing plant. Their knowledge and experience in developing successful minerals processing projects makes them the ideal candidate to manage the construction of our project. The award of the EPCM contract moves the Yangibana Rare Earths Project firmly into development phase to commence project execution and progress to production of our mixed rare earth carbonate by 2022."

Cadence CEO Kiran Morzaria commented: "The appointment of DRA Pacific represents a key step for Yangibana. Not only is it key to the project funding going forward, the EPCM contract terms include a comprehensive performance guarantee linked to ore throughput. Today's announcement provides further validation for our investment strategy into the Yangibana joint venture with Hastings."

– Ends –

For further information:

Cadence Minerals plc	+44 (0) 207 440 0647
Andrew Suckling
Kiran Morzaria
WH Ireland Limited (NOMAD & Broker)	+44 (0) 207 220 1666
James Joyce
James Sinclair-Ford
Novum Securities Limited (Joint Broker)	+44 (0) 207 399 9400
Jon Belliss

 

 

Qualified Person

Kiran Morzaria B.Eng. (ACSM), MBA, has reviewed and approved the information contained in this announcement. Kiran holds a Bachelor of Engineering (Industrial Geology) from the Camborne School of Mines and an MBA (Finance) from CASS Business School.

 

Forward-Looking Statements:

Certain statements in this announcement are or may be deemed to be forward-looking statements. Forward-looking statements are identified by their use of terms and phrases such as ''believe'' ''could'' "should" ''envisage'' ''estimate'' ''intend'' ''may'' ''plan'' ''will'' or the negative of those variations or comparable expressions including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth results of operations performance future capital and other expenditures (including the amount. nature and sources of funding thereof) competitive advantages business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.  Many factors could cause actual results to differ materially from the results discussed in the forward-looking statements including risks associated with vulnerability to general economic and business conditions competition environmental and other regulatory changes actions by governmental authorities the availability of capital markets reliance on key personnel uninsured and underinsured losses and other factors many of which are beyond the control of the Company. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions. The Company cannot assure investors that actual results will be consistent with such forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTPGGUUUUPBGUG

Close

×

Neville Registrars is delighted to welcome Ritorno PLC as the newest addition to its list of client companies.

 

Close